Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Cytokine ; 78: 55-61, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26638029

ABSTRACT

Non-HLA gene polymorphisms have been shown to be associated with the risk of graft-versus-host disease (GVHD) and outcome of allogeneic haematopoietic stem cell transplantation (AHSCT). This study aims to investigate the role of IL6, TNFα, IL10, IL2 and IL12 gene polymorphisms in the outcome of AHSCT in a South East Asian population. A total of 67 patients and 59 donors who underwent HLA-identical matched sibling AHSCT were available for analysis. There was no significant association between the different cytokine genotypes of patients with the incidence and severity of acute GVHD. Patients with IL2 166∗T allele and patients who received donor stem cells who had IL2 166∗G allele appeared to have reduced incidence of cGVHD. Patients who received donor stem cells with IL12 1188∗C allele are found to be associated with better disease free survival. These results suggest a possible role of IL2 and IL12 gene polymorphisms in the outcome of AHSCT in a South East Asian population.


Subject(s)
Cytokines/genetics , Graft vs Host Disease/genetics , Hematopoietic Stem Cell Transplantation , Polymorphism, Genetic , Adolescent , Adult , Asian People , Child , Child, Preschool , Cytokines/physiology , Female , Genotype , Histocompatibility Testing , Humans , Interleukin-12/genetics , Interleukin-2/genetics , Male , Middle Aged , Tissue Donors , Transplantation, Homologous , Young Adult
3.
Vox Sang ; 102(1): 65-71, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21592136

ABSTRACT

BACKGROUND AND OBJECTIVES: Appropriate screening for irregular red-cell antibodies is essential for ensuring transfusion compatibility and for antenatal management of mothers at risk of haemolytic disease of the foetus and newborn. Screening for all relevant antibodies is, however, limited by screening cells that do not express antigens present in the patient and donor population. Technology to artificially incorporate antigens into red cells is currently available and may be an option for customizing screening cells. MATERIALS AND METHODS: We sought to identify retrospectively the changing patterns of alloantibody prevalence in our multiethnic population on change of screening cells. Antibody screening records of 143 501 patients tested from 2004 to 2010 were retrieved and divided into two groups: period-1 (2004-2008) and period-2 (2009-2010). During period-1, standard screening cells were used while in period-2, MUT+Mur+ KODE(™) transformed red cells (kodecytes) were used. RESULTS: Four per cent of samples tested during period-2 were positive on antibody screening compared to 3·2% in period-1. Specific antibodies, excluding anti-D, were identified in 1·66% and 1·52% of patients in period-2 and -1, respectively. When confined to antibodies of clinical significance only, period-2 showed higher alloantibody prevalence of 1·16% as compared to 0·66% in period-1. Antibodies to glycophorin variants of MNS (vMNS) were more commonly detected while antibodies to Lewis antigens declined during period-2. CONCLUSION: Antibodies to vMNS antigens are common in South and East Asian populations and are often missed when using standard screening cells. Use of specifically engineered screening cells to express red-cell antigens artificially is beneficial in detecting the diverse alloantibodies present in our population.


Subject(s)
Antibodies, Monoclonal/chemistry , Asian People/genetics , Erythrocytes/immunology , ABO Blood-Group System/blood , Asia , Ethnicity , Female , Glycophorins/chemistry , Humans , Isoantibodies/chemistry , MNSs Blood-Group System/blood , Male , Phenotype , Pregnancy , Prevalence , Sensitivity and Specificity , Sex Factors
4.
Vox Sang ; 98(3 Pt 1): e295-363, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20432515

ABSTRACT

A critical aspect of blood transfusion is the timely provision of high quality blood products. This task remains a significant challenge for many blood services and blood systems reflecting the difficulty of balancing the recruitment of sufficient donors, the optimal utilization of the donor's gift, the increasing safety related restrictions on blood donation, a growing menu of specialized blood products and an ever-growing imperative to increase the efficiency of blood product provision from a cost perspective. As our industry now faces questions about our standard practices including whether or not the age of blood has a negative impact on recipients, it is timely to take a look at our collective inventory management practices. This International Forum represents an effort to get a snap shot of inventory management practices around the world, and to understand the range of different products provided for patients. In addition to sharing current inventory management practices, this Forum is intended to foster an exchange of ideas around where we see our field moving with respect to various issues including specialty products, new technologies, and reducing recipient risk from blood transfusion products.


Subject(s)
Blood Banks/organization & administration , Inventories, Hospital/organization & administration , Adult , Americas , Asia , Blood Banks/statistics & numerical data , Blood Preservation/methods , Blood Preservation/standards , Blood Preservation/statistics & numerical data , Blood Transfusion/standards , Blood Transfusion/statistics & numerical data , Child , Cryopreservation , Erythrocyte Aging , Europe , Humans , Infant, Newborn , Medical Records , Surveys and Questionnaires , Time Factors
5.
Int J Hematol ; 91(1): 136-9, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20047097

ABSTRACT

The co-occurrence of JAK2 V617F mutation with BCR-ABL reciprocal translocation is uncommon. We report a 60-year-old man who initially presented with phenotype of polycythemia vera (PV), which evolved into chronic myeloid leukemia and back to PV once treatment with imatinib was commenced. JAK2 V617F mutation and BCR-ABL fusion transcripts were detected in the initial sample. However, JAK2 V617F alleles diminished when BCR-ABL mRNA burden increased and reappeared once the patient was commenced on imatinib. The dynamic interaction between JAK2 V617F and BCR-ABL implies that two independent clones exist with the JAK2 V617F clone only achieving clonal dominance when BCR-ABL positive clones are suppressed by imatinib.


Subject(s)
Fusion Proteins, bcr-abl/genetics , Janus Kinase 2/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Polycythemia Vera/complications , Polycythemia Vera/genetics , Antineoplastic Agents/therapeutic use , Benzamides , Disease Progression , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Male , Middle Aged , Piperazines/therapeutic use , Pyrimidines/therapeutic use
6.
Int J Lab Hematol ; 32(2): 215-21, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19566741

ABSTRACT

Individuals with alpha-thalassaemia (ATT), beta-thalassaemia (BTT) and HbE trait (HET) are often initially identified based on haematological parameters. However, the values of these parameters usually overlap with iron deficiency anaemia (IDA) and anaemia of chronic disease (ACD). We evaluated the use of RBC-Y in 156 normal individuals and 332 patients; ATT (n = 37), BTT (n = 61), HET (n = 25), HbH disease (n = 5), ACD (n = 67), IDA (n = 83) and ACD with IDA (n = 54). Diagnostic efficiency was analysed by receiver operating characteristics (ROC). MCH was better compared with RBC-Y in discriminating normal from abnormal with sensitivity and specificity of 94% at a cut-off of 26 pg. The Green and King (G&K) index performed the best in discriminating carriers from IDA and ACD with area under the ROC curve (AUC(ROC)) of 0.81. However, if ACD was excluded, RBC-Y/MCV was a good discriminator for carriers from IDA with AUC(ROC) = 0.845. In general screening of populations with ATT, BTT and HET, we propose that hypochromic individuals be first identified by MCH <26 pg and carriers distinguished within these hypochromic individuals from IDA by using RBC-Y/MCV. However, if the prevalence of ACD were high within the screening population, G&K index would be a more suitable discriminator.


Subject(s)
Anemia, Iron-Deficiency/genetics , Hemoglobin E/genetics , Heterozygote , Thalassemia/genetics , Anemia, Iron-Deficiency/diagnosis , Flow Cytometry , Genetic Variation , Humans , ROC Curve , Reference Standards , Thalassemia/diagnosis
7.
Int J Lab Hematol ; 32(1 Pt 2): 82-7, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19170774

ABSTRACT

Altitude training is sometimes employed by elite endurance athletes to improve their sea level performance. This improvement results from the increased red cell mass consequent upon the boost in erythropoietin (EPO) level that occurs as a response to the relatively hypoxic environment at high altitudes. We measured serum EPO levels together with various red cell and reticulocyte parameters including immature reticulocyte fraction (IRF) in eight national track-endurance cyclists, resident at sea-level, prior to and upon return from an altitude of approximately 1905 m. Reticulocytes and soluble transferrin receptor (sTfR) were significantly increased with reduction in ferritin levels immediately on return from high altitude indicating increased erythropoietic activity. IRF in particular showed a significant peak immediately on return but decline to sub-baseline levels by day 9, and recovery to baseline by day 16. Our results indicate that IRF is a sensitive marker of erythropoietic status in athletes undergoing altitude training and subsequent loss of EPO stimuli on return to sea level.


Subject(s)
Altitude , Bicycling , Erythropoiesis , Erythropoietin/blood , Physical Endurance/physiology , Reticulocyte Count , Adult , Athletes , Humans , Male
8.
Singapore Med J ; 48(3): e74-6, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17342275

ABSTRACT

Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome. We report a 74-year-old man who presented first with Sweet's syndrome and subsequently leukocytosis. He had splenomegaly, a raised vitamin B12 level, serum uric acid and neutrophil alkaline phosphatase score. Cytogenetic study of the marrow was normal and peripheral blood for BCR-ABL gene transcript was not detectable. He subsequently passed away with bronchopneumonia.


Subject(s)
Leukemia, Neutrophilic, Chronic/diagnosis , Aged , Angiogenesis Inhibitors/therapeutic use , Fatal Outcome , Humans , Interferon-alpha/therapeutic use , Leukemia, Neutrophilic, Chronic/blood , Leukemia, Neutrophilic, Chronic/drug therapy , Male , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...